Has Jared Wilkinson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,689 in general payments to Jared Wilkinson, MD across 100 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jared Wilkinson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jared Wilkinson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jared Wilkinson, MD

Pulmonary Disease · Falls Church, VANPI 1699111542

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by United Therapeutics Corporation at 28.8% of the total. 2025 is the largest year on record at $1,500, 7.7 times the $196 reported in 2023. That places this record below the midpoint for pulmonary disease clinicians in VA, where the typical reported total is $1,962.

$2,689in general payments, 2019–2025

Across 100 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

United Therapeutics Corporation$775
Boehringer Ingelheim$388
Actelion Pharmaceuticals US, Inc.$376
AbbVie$175
Bayer$149
Takeda Pharmaceuticals U.S.A., Inc.$127
plus $699 from 15 others

$16,582in research payments, 2019–2025

Across 9 payments — averaging $1842.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim$17K

What the payments were for

Food & beverage$2,61197%
Education$793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
United Therapeutics Corporation	25	$775
Boehringer Ingelheim	15	$388
Actelion Pharmaceuticals US, Inc.	11	$376
AbbVie	7	$175
Bayer	6	$149
Takeda Pharmaceuticals U.S.A., Inc.	4	$127
Melinta Therapeutics, LLC	7	$126
ANI Pharmaceuticals, Inc.	3	$86
Paratek Pharmaceuticals, Inc.	3	$68
Astellas Pharma US Inc	2	$66
Merck	3	$52
Mylan Specialty L.p.	2	$46
Vertex	2	$45
Grifols Shared Services North America, Inc.	1	$42
Vifor Pharma, Inc.	2	$35
Invivyd Inc	2	$31
Insmed, Inc.	1	$25
AstraZeneca	1	$22
Verona Pharma, Inc.	1	$21
Baxter Healthcare	1	$19
Sandoz	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OFEV$138

How this compares

$2,689 in reported general payments places this provider in the 50th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia →

Medicare billing

Part B allowed, 2024

$58,938

Medicare patients

221

Services billed

552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Pantoprazole Sodium	23	$237
Montelukast Sodium	13	$207
Spironolactone	19	$194
Famotidine	13	$128
Prednisone	25	$108

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Falls Church

Steven NathanFalls Church$1.5M
Rabih HalabiFalls Church$604K
Vikramjit KhangooraFalls Church$49K
Shambhu AryalFalls Church$48K
Anne BrownFalls Church$31K
Omar MinaiHopewell$1.3M
Eric LibreAnnandale$302K
Sujoy GillRichmond$296K
Imre NothCharlottesville$256K
Carlos SilvaChesapeake$245K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →